1. Home
  2. TENX vs RSSS Comparison

TENX vs RSSS Comparison

Compare TENX & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.48

Market Cap

73.8M

Sector

Health Care

ML Signal

N/A

Logo Research Solutions Inc

RSSS

Research Solutions Inc

N/A

Current Price

$1.89

Market Cap

71.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
RSSS
Founded
1967
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
73.8M
71.2M
IPO Year
2001
2008

Fundamental Metrics

Financial Performance
Metric
TENX
RSSS
Price
$1.48
$1.89
Analyst Decision
Buy
Strong Buy
Analyst Count
10
3
Target Price
★ $10.29
$3.83
AVG Volume (30 Days)
★ 1.4M
35.6K
Earning Date
11-05-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 125.00
EPS
N/A
★ 0.02
Revenue
N/A
★ $28,793,922.00
Revenue This Year
N/A
$1.40
Revenue Next Year
N/A
$5.18
P/E Ratio
★ N/A
$21.00
Revenue Growth
N/A
★ 2.77
52 Week Low
$1.31
$1.77
52 Week High
$19.40
$3.38

Technical Indicators

Market Signals
Indicator
TENX
RSSS
Relative Strength Index (RSI) 35.62 45.43
Support Level $1.34 $1.78
Resistance Level $2.01 $2.36
Average True Range (ATR) 0.12 0.09
MACD 0.00 0.01
Stochastic Oscillator 6.25 40.00

Price Performance

Historical Comparison
TENX
RSSS

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from the cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

Share on Social Networks: